Life-Threatening Cutaneous Bleeding in Childhood Klippel-Trenaunay Syndrome Treated With Oral Sirolimus
Klippel-Trenaunay syndrome (KTS) is characterized by the triad of cutaneous capillary malformations (port-wine stains), asymmetrical disturbed growth of soft tissues and/or bone, and venous and lymphatic malformations. 1 Prolonged and recurrent cutaneous bleeding from ulceration of the capillary and/or venous and/or lymphatic malformation can be life-threatening. 2 We report for the first time to our knowledge a case of Klippel-Trenaunay syndrome treated by oral sirolimus.
Report of a Case | A 13-month-old boy from Conakry, Guinea, was referred for assessment of recurrent cutaneous bleeding of the right lateral thigh complicated by chronic anemia. The par-ents had noted bleeding, either spontaneous or during dressing change, for 2 months despite the application of hemostatic dressings. Physical examination revealed a hypertrophic lower right limb with multiple port-wine stains centered by tumefactions 2 to 13 cm long composed of grouped hemorrhagic vesicles and crust ( Figure 1A) . Laboratory investigations revealed the following: hemoglobin level, 8.8 g/dL (normal range [NR], 10-14 g/dL), hematocrit, 29% (NR, 30%-42%), platelet count of 403 × 10 3 /μL (NR, 150 × 10 3 /μL to 400 × 10 3 /μL), fibrinogen, 30 mg/dL (NR, 150-400 mg/dL), and D-dimer, greater than 4 μg/mL (NR, <0.5 μg/mL ). (To convert fibrinogen to micromoles per liter, multiply by 0.0294; Ddimer to nanomoles per liter, multiply by 5.476.) Magnetic resonance imaging (MRI) of the right leg showed a microcystic lymphatic malformation with muscular infiltration of the posterior compartment of the thigh and hypoplasia of the deep veins associated with a persistent embryonic lateral marginal vein of the thigh (Figure 2A) . A diagnosis was made of KTS complicated by chronic cutaneous bleeding induced by extensive microcystic lymphatic cutaneous malformation and lateral thigh vein. Due to the partially atretic deep venous system and the extensive muscular infiltration of the lymphatic malformation, treatment by surgery, sclerotherapy, catheter embolization, and compression were ruled out. Photocoagulation using the Nd:YAG or fractional carbon dioxide laser was infeasible due to the need for multiple sessions under general anesthesia and the risk of recurrence.
After informed parental consent, treatment with oral sirolimus was started at 0.8 mg/m 2 per dose twice daily along with cotrimoxazole for Pneumocystis prophylaxis. The bleeding stopped completely after 48 hours. Subsequent dosing of sirolimus was adjusted to 1 mg/m 2 per dose to maintain a goal drug level around 10 ng/mL. The patient's anemia was corrected and D-dimer level normalized 1 and 5 months, respectively, after starting sirolimus treatment. In the following 6 months, a consistent and gradual reduction in the thickness of the tumefaction and its hemorrhagic component ( Figure 1B ) was noted and confirmed by MRI ( Figure 2B ). An attempt to terminate sirolimus treatment resulted in a rapid relapse of minimal cutaneous bleeding after 2 to 3 days, and sirolimus therapy was restarted promptly at the same dosage. No clinically significant adverse effect was observed after 10 months, and treatment by oral sirolimus was maintained at the same dose.
Discussion | Recent observations have shown that KTS is caused by heterozygous somatic gain-of-function PIK3CA mutations in a mosaic pattern, leading to inappropriate activation of the P13K/AKT/mTOR pathway, and belongs to the PIK3CArelated overgrowth spectrum (PROS). 3 Recent publications emphasize the potential interest of sirolimus, an inhibitor of mTOR activity, as a treatment option for cutaneous vascular malformations and PROS. 4, 5 Sirolimus has been used successfully with a good safety profile in more than 70 case reports of vascular anomalies with lymphatic components, 6 and phase 2 studies are ongoing to assess its efficacy and safety in various complex vascular malformations, including KTS (clinicaltrials .gov NCT00975819, NCT02509468, and NCT01811667). 
